[go: up one dir, main page]

BRPI0417858A - composto, composição farmacêutica, e, uso de uma composição farmacêutica - Google Patents

composto, composição farmacêutica, e, uso de uma composição farmacêutica

Info

Publication number
BRPI0417858A
BRPI0417858A BRPI0417858-0A BRPI0417858A BRPI0417858A BR PI0417858 A BRPI0417858 A BR PI0417858A BR PI0417858 A BRPI0417858 A BR PI0417858A BR PI0417858 A BRPI0417858 A BR PI0417858A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compound
indolylsulfanyl
treatment
general formula
Prior art date
Application number
BRPI0417858-0A
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Jimmy Sejberg
Morten Bang Norgaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI0417858A publication Critical patent/BRPI0417858A/pt
Publication of BRPI0417858B1 publication Critical patent/BRPI0417858B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DE UMA COMPOSIçãO FARMACêUTICA". A presente invenção refere-se aos derivados de anilina de fórmula geral I e ao seu uso como inibidores da recaptação de serotonina e preferivelmente também aos inibidores da recaptação de norepinefrina no tratamento de depressão, ansiedade, distúrbios afetivos, distúrbios de dor, distúrbio de hiperatividade com deficiência de atenção (ADHD) e incontinência urinária de estresse.
BRPI0417858-0A 2003-12-23 2004-12-21 Derivative compounds of aniline and pharmaceutical composition that understand it BRPI0417858B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53259303P 2003-12-23 2003-12-23
US60/532,593 2003-12-23
DKPA200301923 2003-12-23
DKPA200301923 2003-12-23
PCT/DK2004/000894 WO2005061455A1 (en) 2003-12-23 2004-12-21 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri

Publications (2)

Publication Number Publication Date
BRPI0417858A true BRPI0417858A (pt) 2007-04-27
BRPI0417858B1 BRPI0417858B1 (pt) 2017-10-10

Family

ID=34712442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417858-0A BRPI0417858B1 (pt) 2003-12-23 2004-12-21 Derivative compounds of aniline and pharmaceutical composition that understand it

Country Status (18)

Country Link
US (4) US7563908B2 (pt)
EP (1) EP1701940B1 (pt)
JP (3) JP4090491B2 (pt)
AT (1) ATE396970T1 (pt)
AU (1) AU2004303461B2 (pt)
BR (1) BRPI0417858B1 (pt)
CY (2) CY1108230T1 (pt)
DE (1) DE602004014190D1 (pt)
DK (1) DK1701940T3 (pt)
ES (1) ES2303960T3 (pt)
HR (2) HRP20080274T3 (pt)
IL (1) IL176111A (pt)
MX (1) MXPA06007172A (pt)
PL (1) PL1701940T3 (pt)
PT (1) PT1701940E (pt)
RS (1) RS50589B (pt)
SI (1) SI1701940T1 (pt)
WO (1) WO2005061455A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1701940T3 (da) * 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2009538117A (ja) * 2006-03-22 2009-11-05 ハー・ルンドベック・アクチエゼルスカベット うつ病を処置するための化合物を同定する方法
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
CN101563320B (zh) * 2006-09-28 2012-05-30 H.隆德贝克有限公司 用于治疗情感障碍的[2-(6-氟-1h-吲哚-3-基硫烷基)苄基]甲胺
EP2074091B1 (en) * 2006-09-28 2015-01-07 H. Lundbeck A/S [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
WO2009042632A2 (en) * 2007-09-24 2009-04-02 H. Lundbeck A/S Combination therapy related to serotonin dual action compounds
TW200938189A (en) * 2008-03-13 2009-09-16 Lundbeck & Co As H [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
MX2011000494A (es) * 2008-07-15 2011-02-25 Hoffmann La Roche Derivados de indolilo e indazolilo substituidos y usos de los mismos.
ES2646834T3 (es) * 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
JP2016530209A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ビニルオートタキシン阻害剤化合物
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
HUE055213T2 (hu) 2013-11-22 2021-11-29 Sabre Therapeutics Llc Autotaxin inhibitor vegyületek
CA2986759C (en) 2015-05-27 2025-06-17 Sabre Therapeutics Llc AUTOTAXIN INHIBITORS AND THEIR USES
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003023A (en) * 1930-10-16 1935-05-28 Westinghouse Electric & Mfg Co Mercury vapor or noble gas rectifier with arc control
US3803143A (en) 1969-09-08 1974-04-09 Eisai Co Ltd 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US4055665A (en) 1974-11-25 1977-10-25 Merck & Co., Inc. Treating arrythmia with phenylthioaralkylamines
US4056632A (en) 1975-07-21 1977-11-01 Burroughs Wellcome Co. 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0396827A1 (en) 1989-05-09 1990-11-14 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof
GB8912971D0 (en) 1989-06-06 1989-07-26 Wellcome Found Halogen substituted diphenylsulfides
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
ATE190608T1 (de) * 1991-11-25 2000-04-15 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
KR100533431B1 (ko) 1995-01-23 2006-05-03 다이이치 아스비오파마 가부시키가이샤 허혈성질환에기인하는증상의완화또는치료용약제및이에유용한화합물
ATE195125T1 (de) 1995-11-06 2000-08-15 Dsm Nv Verfahren zur de-esterifikation
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
US5906078A (en) * 1996-10-09 1999-05-25 Gallagher-Kaiser Corporation Retaining strip for sheet covered enclosures
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
DE19756036A1 (de) * 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6333146B1 (en) 1999-03-10 2001-12-25 Fuji Photo Film Co., Ltd. Methine compound and silver halide photographic material containing the same
EA200101017A1 (ru) 1999-04-02 2002-04-25 Айкос Корпорейшен Ингибиторы связывания lfa-1 с icam и их использование
AU780725B2 (en) 1999-04-30 2005-04-14 Trustees Of The University Of Pennsylvania, The Spect imaging agents for serotonin transporters
MXPA02001160A (es) 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
PL355289A1 (en) * 1999-10-13 2004-04-05 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
NZ519647A (en) 1999-12-30 2004-02-27 H Substituted phenyl-piperazine derivatives, their preparation and use
DE60011817T2 (de) 1999-12-30 2005-07-14 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl und -tetrahydropyridyl-derivate
DE60009154D1 (de) 1999-12-30 2004-04-22 Lundbeck & Co As H Phenylpiperazinyl-derivate
WO2001064206A2 (en) 2000-02-29 2001-09-07 Integriderm, Inc. Inhibitors of melanocyte tyrosinase as topical skin lighteners
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US6455738B1 (en) 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
WO2002015910A1 (en) 2000-08-18 2002-02-28 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
BR0113445A (pt) 2000-09-01 2005-04-12 Fmc Corp Composto, composição, e, método para o controle de insetos
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
DE60129148T2 (de) 2000-10-06 2008-02-28 Biocompatibles Uk Ltd., Farnham Zwitterionische polymere
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
DE60131675T2 (de) 2000-11-14 2008-11-20 Merck Patent Gmbh Neue verwendung von substanzen mit kombinierten 5-ht1a agonistischen und serotonin reuptake inhibitor-aktivitäten
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
DE60218037T2 (de) 2001-06-07 2007-08-23 F. Hoffmann-La Roche Ag Neue indolderivate mit affinität zum 5-ht6-rezeptor
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
HUP0401924A3 (en) 2001-11-14 2009-07-28 Schering Corp Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
MXPA04006119A (es) 2001-12-21 2004-11-01 Lundbeck & Co As H Derivados aminoindano como inhibidores de la absorcion de la serotonina y de la norepinefrina.
EP1465933B1 (en) 2002-01-16 2007-08-29 Biocompatibles UK Limited Polymer conjugates
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
ATE382154T1 (de) 2002-03-01 2008-01-15 Fujifilm Corp Farbphotographisches lichtempfindliches silberhalogenidmaterial
JP4151842B2 (ja) 2002-03-04 2008-09-17 独立行政法人科学技術振興機構 新規なホスホン酸アミド化合物、その製造方法及び用途
EP2557139B1 (en) 2002-03-29 2021-05-05 Massachusetts Institute Of Technology Light emitting device including semiconductor nanocrystals
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7217732B2 (en) 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
CA2498946A1 (en) 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag 2,4-substituted indoles and their use as 5-ht6 modulators
ATE362469T1 (de) 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
WO2004028559A1 (en) * 2002-09-26 2004-04-08 The Board Of Trustees Of The University Of Illinois Anti-angiogenic fragments of pigment epithelium-derived factor (pedf)
US20040137389A1 (en) 2002-12-19 2004-07-15 Kouta Fukui Heat-developable light-sensitive material
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
US7189501B2 (en) 2002-12-27 2007-03-13 Fuji Photo Film Co., Ltd. Silver halide color photographic photosensitive material
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
US7820753B2 (en) 2003-02-05 2010-10-26 Biocompatibles Uk Limited Block copolymers
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2005035516A1 (ja) 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
US7229751B2 (en) 2003-11-20 2007-06-12 Konica Minolta Medical & Graphic, Inc. Silver salt photothermographic dry imaging material and image forming method using the same
WO2005060711A2 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
DK1701940T3 (da) * 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
SE528250C2 (sv) 2004-02-27 2006-10-03 Calignum Technologies Ab Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen
JP4569142B2 (ja) 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
JP4448730B2 (ja) 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
US20090156471A1 (en) 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
EP1793272A4 (en) 2004-08-24 2008-01-23 Fujifilm Corp PHOTOGRAPHIC PHOTOSENSITIVE COLOR MATERIAL BASED ON SILVER HALIDE AND METHOD OF FORMING IMAGES
CA2582658A1 (en) 2004-10-08 2006-04-13 Banyu Pharmaceutical Co., Ltd. Method for producing thioether compound
WO2006063606A1 (en) 2004-12-16 2006-06-22 Pirelli & C. S.P.A. Process for manufacturing a thermoplastic elastomeric material

Also Published As

Publication number Publication date
IL176111A0 (en) 2006-10-05
JP4091648B2 (ja) 2008-05-28
BRPI0417858B1 (pt) 2017-10-10
PT1701940E (pt) 2008-07-30
CY1108230T1 (el) 2014-02-12
MXPA06007172A (es) 2006-08-23
HRP20110400T1 (hr) 2011-06-30
JP2008110984A (ja) 2008-05-15
AU2004303461A1 (en) 2005-07-07
AU2004303461B2 (en) 2011-04-28
US7563908B2 (en) 2009-07-21
US20080176922A1 (en) 2008-07-24
DK1701940T3 (da) 2008-09-08
US7737171B2 (en) 2010-06-15
ES2303960T3 (es) 2008-09-01
DE602004014190D1 (de) 2008-07-10
RS50589B (sr) 2010-05-07
US7652150B2 (en) 2010-01-26
IL176111A (en) 2011-10-31
JP4090491B2 (ja) 2008-05-28
US20060160880A1 (en) 2006-07-20
ATE396970T1 (de) 2008-06-15
US20080214644A1 (en) 2008-09-04
WO2005061455A1 (en) 2005-07-07
CY1111733T1 (el) 2015-10-07
EP1701940B1 (en) 2008-05-28
EP1701940A1 (en) 2006-09-20
HRP20080274T3 (en) 2008-12-31
JP2007277254A (ja) 2007-10-25
US20080214645A1 (en) 2008-09-04
PL1701940T3 (pl) 2008-11-28
SI1701940T1 (sl) 2008-10-31
JP2007515436A (ja) 2007-06-14
US7737170B2 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
SE0401971D0 (sv) Piperidne derivatives
SE0301653D0 (sv) Novel compounds
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
SE0401342D0 (sv) Therapeutic compounds
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
SE0403171D0 (sv) New compounds
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE440833T1 (de) Antithrombotische diamide
SE0302546D0 (sv) New compounds
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
DE602004031410D1 (de) Inden derivate als pharmazeutika
MXPA05009282A (es) Derivados de anilina sustituidos.
TW200745122A (en) New compounds I
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
EA200602180A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи
TW200744612A (en) New combination
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2610 DE 12-01-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.